Objectives-Tenidap, a new anti-
1-25-5 ,ug/ml there was a small but significant increase in proliferation compared with controls. A further increase in growth was obtained when cells were incubated with Tenidap + IL-I, TNF or bFGF, and this was significantly higher than in the presence of any cytokine alone. Stimulation of IL-1 induced growth by Tenidap was reduced by addition of high levels of exogenous PGE2 (100 ng/ml) although growth was still higher than in IL-I alone. Conclusions-Depending on concentration, Tenidap may inhibit or stimulate synovial fibroblast growth. Our (RA) although it is still unclear which factors are responsible for driving this phenomenon. Many growth factors/cytokines have been implicated, including platelet derived growth factor (PDGF),' epidermal growth factor (EGF),2 acidic and basic fibroblast growth factors (FGFs),3 4 tumour necrosis factor alpha (TNF),5 as well as combinations of cytokines (for example, interleukin-1 and transforming growth factor 0).6 The major source of these factors is believed to be leukocyte populations, particularly mononuclear phagocytes, which infiltrate the rheumatoid joint during inflammation.
Synovial fibroblasts are likely to play an important role in the inflammatory process since they have been shown to produce various mediators, including cytokines,7 prostaglandins,8 and proteolytic enzymes such as collagenase and stromelysin.' 9 They may also orchestrate the responses of other cells within the synovium and may affect the survival of lymphocytes and other haemopoietic cells within the joint.1"
The proliferation of synovial fibroblasts may be affected not only by factors produced within the joint but also by various anti-inflammatory drugs and second-line agents administered to patients with RA. Since most patients with RA are on such agents it is difficult to assess the role of individual growth promoting (or inhibiting) factors produced in vivo. For example, non-steroidal anti-inflammatory drugs (NSAIDS) inhibit production of prostanoids such as prostaglandin E2 (PGE2) which is generally inhibitory to fibroblast cell growth. It has been shown that treatment with the NSAID indomethacin increases synovial fibroblast cell growth in vitro in the presence of interleukin-1 i or TNF." Furthermore IL-I and PDGF act synergistically to stimulate synovial fibroblast proliferation in the presence of indomethacin.' Other cyclo-oxygenase inhibitors and glucocorticoids have similar enhancing effects on IL-1 induced fibroblast proliferation. " l In contrast, the second line agent D-penicillamine causes suppression of human skin fibroblasts in the presence of physiological levels of copper sulphate.'2 This inhibition was attributed to the production of hydrogen peroxide in the presence of these agents. Thus drugs which affect the production of growth inhibitory ( dissolved in DMSO, at a concentration of 10 mg/ml before dilution in culture medium. Indomethacin was prepared in a similar way. The following cytokines were used alone or in combination with Tenidap: IL-1 alpha (human recombinant, 0X1-10 ng/ ml), TNF alpha (human recombinant, 0X1-10 ng/ml), IL-6 (human recombinant, 0*5-5 ng/ ml), basic FGF (human recombinant, 0X1-10 ng/ml), TGF beta (from human platelets, 0X1-5X0 ng/ml). TGF beta was obtained from Sigma. All other cytokines were from British Biotechnology Ltd.
3) PGE2 MEASUREMENT PGE2 was measured by a standard radioimmunoassay (Amersham) on cell free supernatants from the 96 well growth assay plates. Supernatants were stored at -70°C before use.
STATISTICAL METHODS
The Wilcoxon test for matched pairs (non parametric data) or the paired t test (parametric data) was employed to determine the significance of the difference in cell growth between fibroblast cultures treated with or without Tenidap. All statistics were calculated using the Number Cruncher Statistical System.
Results

CELL PROLIFERATION
(1) Tenidap A range of concentrations of Tenidap sodium (0a 1-80 pug/ml) were tested in our proliferation assays. In most cell cultures, Tenidap above 10 ,ug/ml in SFM inhibited cell proliferation. At higher concentrations (>20 ,ug/ml) Tenidap Tenidap concentration (,ug/rnl) Tenidap concentration (pLg/ml Tenidap induced proliferation of fibroblasts in vitro was dependent on drug concentration. Little or no effect on cell proliferation was seen at <1-25 ,ug/ml while >10 ,ug/ml growth was inhibited. At higher concentrations (>15 ,ug/ ml) Tenidap was toxic to cells in SFM although the toxicity was significantly reduced by incubating cells in SFM containing higher levels of BSA, or in medium with 100% FCS. This may be explained by increased binding of Tenidap to protein under these conditions. More than 99% of Tenidap is reversibly bound to human plasma proteins over the range of 1-100 tg/ml. (Pfizer Central Research). It has been shown previously that indomethacin enhances IL-1 and TNF induced proliferation of synovial fibroblasts in the presence of serum,"1 probably through inhibition of PGE2 production. We have confirmed this using a range of indomethacin concentrations in SFM. However, the maximal growth stimulation produced in the presence of IL-I + indomethacin was less than the maximal stimulation by IL-I + Tenidap. Furthermore, high levels of PGE2 (100 ng/ml) only caused partial inhibition of the cell growth induced by Tenidap + IL-1. Exogenous PGE2 added at concentrations equivalent to those found in IL-I treated cultures (2-3 ng/ml) had little or no effect on the growth of cells in Tenidap + IL-1. Recent work by Taylor et al6 has questioned the concept that PGE is an important growth inhibitor in synovial fibroblasts since cytokine combinations which stimulated high levels of PGE production also caused increased proliferation. Our results suggest that augmentation of synovial fibroblast proliferation by Tenidap cannot be explained by inhibition of PGE2 production alone. This suggestion is reinforced by the demonstration that Tenidap is able to augment synovial fibroblast proliferation in SFM alone or in the presence of cytokines such as bFGF and IL-6 which do not stimulate PGE2 production.20 21 In contrast to our results with Tenidap, a previous study showed that indomethacin had no potentiating effect on bFGF induced synovial proliferation. 20 There Tenidap. In our experience the variations in growth between cell cultures were not related to the type of disease or severity of disease in the patients from which they were obtained. Moreover, although most cell cultures exhibited slower growth with increasing passage number, some cell cultures still showed significant proliferation at passage numbers >25. Even in slower growing cells at high passage numbers (>20) Tenidap caused significant augmentation of cytokine induced growth.
We found in both serum free and serum containing media that Tenidap stimulated cell proliferation with and without cytokines. It should be pointed out that our serum free medium contained some protein (0X1% BSA) as well as transferrin, selenium and the progression factor, insulin, which may act synergistically with other growth factors.23 Indeed, we have found that insulin synergises with IL-1 to increase growth of synovial fibroblasts (unpublished observations). In contrast to many previous studies we used an assay that reflects the actual change in cell numbers. Although [3H] thymidine incorporation is widely considered to correlate with cell growth, this type of assay can produce misleading results since increased thymidine uptake does not always correlate well with increases in cell number.3 24 25 Also, the full effect of a particular cytokine on cell growth may be underestimated by [3H] thymidine incorporation which is usually carried out over a relatively short time period (24-48 hours). Release of other growth factors from the cytokine treated cells may occur at some time after initial stimulation so that the eventual increase in fibroblast numbers results from an indirect autocrine mechanism.26 In our study synovial fibroblasts continued to proliferate over the seven day culture period. Although changes in cell number were measurable after two to three days, differences between treatments were more apparent after seven days. 
